Clinical Trials Logo

Advanced Kidney Cancer clinical trials

View clinical trials related to Advanced Kidney Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05485896 Recruiting - Clinical trials for Advanced Kidney Cancer

Pembrolizumab Plus Lenvatinib in Stage III-IV RCC

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer. Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles pre-operation and patients need to continue taking the drug for a year after surgery.

NCT ID: NCT05485883 Recruiting - Clinical trials for Advanced Kidney Cancer

Tislelizumab Plus Lenvatinib in Stage III-IV RCC

TILUR
Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects